MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL
Vignesh T. Packiam(Rutgers, The State University of New Jersey), Gary D. Steinberg(Rush University Medical Center), Donald L. Lamm(The University of Texas System), Kirsten Dorr, Daniel A. Barocas(Vanderbilt University Medical Center), Ronald L. Davis(Wake Forest University), John Gutheil, Arthur Kuan(Genesys (United States)), A. Karim Kader(University of California San Diego), Karim Chamie(University of California, Los Angeles)
Cited by 13
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487